In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US Bioscience Inc.

Division of Amarantus Bioscience Inc./Power3 Medical Products Inc./ProteEx Inc.

Latest From US Bioscience Inc.

Transactions 1999: Dealmaking for the New Economy

The number of early-stage deals plummeted as large drug companies fought their way through mergers and other late-stage deals designed to boost near-term earnings. Drug companies also looked to mergers to build up sales forces and, by building bigger-selling products, to compensate for the lack of R&D productivity. Meanwhile, biotechs, with valuations at record levels, looked to find deals that would allow them to keep the upside of their products and move their share prices up.

BioPharmaceutical Medical Device

Why the Drug Delivery Industry Can Consolidate

Drug delivery companies have been consolidating with a fury over the last twelve months, unlike biotechs. The difference: delivery firms have plenty of drug service companies to sell to (other drug delivery firms, distributors, generic houses), while biotechs can only sell to Big Pharma--which doesn't want to buy them.

BioPharmaceutical Business Strategies

Special Delivery

Thanks to injection-only delivery, large-molecule drugs have always been seen by Big Pharma as marketplace duds. Companies with delivery alternatives have languished in the dark. Someone's turned the light on.

BioPharmaceutical Medical Device

Elan & Athena: Selling out, Trading up

Athena's frustration with Wall Street and with its Big Pharma partners clearly led to its willingness to listen to Elan's acquisition offer-other similarly placed biotechs are likely to abandon strategies focused on independence.

BioPharmaceutical Strategy
See All

Company Information